Biocon launches biosimilars - Bosaya' and Aukelso' in U.S.

India, April 8 -- Biocon announced the commercial launch of Bosaya' (denosumab-kyqq) and Aukelso' (denosumab kyqq) in the United States.Bosaya' (biosimilar to Prolia') and Aukelso' (biosimilar to Xgeva') are now available by prescription nationwide through specialty pharmacies and healthcare providers.Both products have been previously approved and granted interchangeable designation by the U.S. Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws.

Published by HT Digital Content Services with permission from Pivotal Sources....